GLP-1 Drugs and Exercise: Fitness, Heart Rate and Training

A falling weight does not tell you whether your fitness is improving. In a randomized liraglutide study, adding structured exercise improved measured physical function and aerobic fitness compared with medication alone. Current semaglutide and tirzepatide labels also report small average increases in resting heart rate. Those findings address different outcomes: fitness, body weight and pulse should each be interpreted on their own terms¹²³⁴.

For someone who runs, cycles or lifts, this creates a useful set of questions. Can you train consistently? Are you eating and drinking enough to support normal activity? Has your resting pulse changed, and are there symptoms with it? A body-fat estimate cannot answer those questions.

What the exercise trial actually tested

The S-LiTE trial randomized 195 adults with obesity after an initial low-calorie diet to a year of exercise, liraglutide, both treatments or placebo. The exercise intervention included supervised sessions and individual activity. It was a trial of weight-loss maintenance in people without diabetes, rather than a performance study in trained athletes².

A 2026 secondary analysis examined physical fitness in 193 participants from that study. Compared with liraglutide alone, the combination improved stair-climb time by 1.2 seconds (95% confidence interval 0.6–1.9) and peak oxygen consumption by 3.0 mL/min/kg of fat-free mass (0.5–5.5). Exercise alone produced similar fitness benefits; liraglutide alone did not improve physical fitness¹.

The distinction matters. This supports exercise as part of obesity care. It does not establish that liraglutide enhances sport performance, or that the same changes will occur with semaglutide, tirzepatide or every exercise routine. The newer paper is an additional analysis of the original trial, not an independent replication.

Why the units on a fitness result matter

Oxygen consumption can be reported as an absolute quantity or divided by body weight. If body weight decreases, a value expressed per kilogram can improve even without a corresponding increase in absolute oxygen consumption. A lighter body may also make a stair task easier. Neither observation makes the improvement meaningless; it changes what the measurement tells you.

The fitness analysis specifically evaluated peak oxygen consumption relative to fat-free mass and included an objective stair task and strength assessment¹. Its reported unit is per kilogram of fat-free mass, which should not be shortened to per kilogram of body weight.

That also puts a smartwatch trend in perspective. A consumer estimate is not the same test as measured oxygen consumption during a supervised exercise assessment. Read the device's explanation of its metric, and consider the trend alongside actual activity and symptoms. A single fitness score cannot establish that a medication improved endurance.

Resting heart rate can rise during treatment

The Wegovy label reports average resting heart-rate increases of 1–4 beats per minute compared with placebo in adult injection weight-reduction trials. The Zepbound label reports mean increases of 1–3 beats per minute, versus no increase with placebo, in its pooled weight-reduction studies³⁴. These are study averages; an individual change can differ.

Resting pulse, pulse during exercise and aerobic fitness are different measurements. A higher number during a hard session does not automatically identify the medicine as the cause, and a small average trial increase does not make new palpitations unimportant. The Wegovy label calls for regular heart-rate monitoring and asks patients to report palpitations or a racing heartbeat at rest³.

Bring a pattern to the discussion: when the change began, whether readings were taken at rest, what symptoms occurred and whether eating, fluids or other medicines changed. Do not turn a trial average into a personal threshold for pushing through symptoms.

Strength and lean mass need separate attention

A body-composition scan estimates tissue compartments; it does not directly measure what you can lift or how you move. Fat-free mass also contains more than skeletal muscle. Tracking function alongside body composition is therefore useful when weight changes¹. Our semaglutide and tirzepatide muscle-loss review covers that tissue question in more detail.

The joint advisory from four nutrition and obesity organizations recommends assessing diet, activity, muscle function and the ability to sustain healthy habits during GLP-1 treatment. It supports resistance exercise and appropriate nutrition within care, rather than treating appetite suppression as the whole plan⁵. A supplement purchase alone does not show that muscle function has been preserved.

Bone density is another distinct outcome. If previous fractures or known low bone density affect exercise choices, use our bone-density and exercise review to frame a discussion with the clinician or physical therapist responsible for your care.

When symptoms should change the workout

Repeated vomiting, inability to maintain fluids, or a marked decline in normal daily function deserves clinical attention. Semaglutide and tirzepatide labels warn about acute kidney injury associated with volume depletion. They also highlight hypoglycemia risk, particularly with insulin or medicines that stimulate insulin release³⁴. A medication review is more useful than assuming every difficult workout has the same explanation.

Chest pain, fainting or severe breathlessness needs urgent medical assessment. A training target is not a reason to continue through those symptoms. For less acute problems, describe what you can no longer do and what happens when you try; that gives a clinician more useful information than an isolated wearable score.

Persistent GLP-1 nausea can make food and fluids difficult. Report the limitation rather than interpreting every missed meal as treatment success. Individual needs vary, so this article does not supply a universal fluid, carbohydrate or protein prescription.

Is there a best workout day after an injection?

The cited trials do not establish a universal rule for scheduling races, heavy lifting or long runs around a weekly injection. The exercise trial used daily liraglutide; it cannot establish the best day after weekly semaglutide or tirzepatide. Nor does it support changing medication doses to accommodate a training calendar¹².

A useful plan accounts for your current training, symptom pattern and medical conditions. Discuss significant changes with the prescriber and, when appropriate, a dietitian or qualified exercise professional. The question is how to make activity sustainable while treatment is reviewed, rather than how to copy a stranger's medication schedule.

For the broader research on performance claims, our peptides for endurance review separates human outcomes from animal experiments. The strongest direct finding here remains specific: structured exercise improved fitness during a liraglutide weight-maintenance trial. It gives active people a reason to keep function in the conversation, without promising a faster race time.